Britta Lamottke - Concepedia

Author

Britta Lamottke

Charité - Universitätsmedizin Berlin

Also Known As

B Lamottke, Britta Lamottke, Lamottke, Britta

Publications

824

Citations

H-Index

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin Zero to Three Novartis (United States)Novartis (Switzerland)Novartis Institutes for BioMedical Research

About

Britta Lamottke is an author at Charité - Universitätsmedizin Berlin specializing in medicine, immunology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	360
2	Immunology	5	5	286
3	Cell Biology	2	2	37
4	Cellular Therapies	1	1	33
5	Marrow Transplantation	1	1	33

Britta Lamottke

Publications

429

Citations

H-Index

Page 1

	Year	Citations
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma Ulrike Heider, Jessica Rademacher, Britta Lamottke, European Journal Of Haematology Proteasome InhibitorsChemoprevention StrategyImmunologyProteasome Inhibitor BortezomibPathology	2009	172
A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency Katharina Wimmer, Andreas Beilken, R. Nustede, Familial Cancer Genome InstabilitySomatic VariantGenetic DisorderMedicineGenetics	2016	74
Serum concentrations of DKK‐1 decrease in patients with multiple myeloma responding to anti‐myeloma treatment Ulrike Heider, Martin Kaiser, Maren Mieth, European Journal Of Haematology	2008	69
Synergistic action of the novel HSP90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma Martin Kaiser, Britta Lamottke, Maren Mieth, European Journal Of Haematology Hematological MalignancyTumor BiologySequential IncubationMedicineHistone Deacetylase Inhibitors	2009	44
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors Agnes Bonifacius, Britta Lamottke, Sabine Tischer‐Zimmermann, Journal of Clinical Investigation Cell TherapyImmunologyTransplantation MedicineImmunotherapyT Cell Product	2023	33
The novel, orally bioavailable HSP90 inhibitor NVP‐HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases Britta Lamottke, Martin Kaiser, Maren Mieth, European Journal Of Haematology Tumor BiologyChemoprevention StrategyMedicineCycle ArrestApoptosis	2012	25
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma Ivana von Metzler, Ulrike Heider, Maren Mieth, Experimental Cell Research Hematological MalignancyMedicineMalignant Blood DisorderImmunologyImmune Checkpoint Inhibitor	2009	12

Page 1